Trevi Therapeutics, Inc. (TRVI)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20267 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Trevi Therapeutics, Inc.’s names, not what it holds today.
19 published
3 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Apr 15, 2025 | 12,274,696 | Methods of administering nalbuphine | Pharmaceuticals | Trevi Therapeutics, Inc. |
| May 30, 2023 | 11,660,296 | Treatment of chronic cough, breathlessness and dyspnea | Pharmaceuticals | Trevi Therapeutics, Inc. |
| Mar 26, 2019 | 10,238,646 | Methods for treating pruritus | Pharmaceuticals | Trevi Therapeutics, Inc. |
| Apr 18, 2017 | 9,624,233 | Compounds for treating pruritic conditions | Organic fine chemistry | Trevi Therapeutics, Inc. |
| Mar 24, 2015 | 8,987,289 | Methods for treating pruritus | Pharmaceuticals | Trevi Therapeutics, Inc. |
| Jan 27, 2015 | 8,940,753 | Methods for treating pruritis | Pharmaceuticals | Trevi Therapeutics, Inc. |
| Jan 28, 2014 | 8,637,538 | Methods for treatment of pruritis | Pharmaceuticals | Trevi Therapeutics, Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Nov 6, 2025 | 2025/0339424 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Jul 3, 2025 | 2025/0213552 | METHODS OF ADMINISTERING NALBUPHINE | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Jan 30, 2025 | 2025/0032480 | METHODS FOR TREATING PRURITUS | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Dec 26, 2024 | 2024/0423975 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Oct 26, 2023 | 2023/0338367 | TREATMENT OF PRURIGO NODULARIS | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Dec 29, 2022 | 2022/0409613 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Nov 3, 2022 | 2022/0347171 | TREATMENT OF PRURIGO NODULARIS | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
| Aug 25, 2022 | 2022/0265640 | METHODS OF ADMINISTERING NALBUPHINE | Pharmaceuticals | TREVI THERAPEUTICS, INC. · patent 12,274,696 granted from it |
| Jul 14, 2022 | 2022/0218697 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Pharmaceuticals | TREVI THERAPEUTICS, INC. · patent 11,660,296 granted from it |
| Jan 23, 2020 | 2020/0022974 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Pharmaceuticals | TREVI THERAPEUTICS, INC. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.